Renal Cell Cancer

• SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients
• ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Zurich November 2018
• Participants Clinical Case Discussion: Systemic Therapy in Metastatic RCC
• Debate: No, Immunotherapy is not the Standard First-line Therapy for mRCC
• Debate: Yes, Immunotherapy is the Standard First-line Therapy for mRCC
• Participants Clinical Case Discussion: Case of Metastatic Clear Renal Cancer with Treatment with More that 5 Agents
• mRCC: Immunotherapy
• mRCC: Anti-angiogenic Therapy
• Participants Clinical Case Discussion: Metastatic Kidney Cancer
• Participants Clinical Case Discussion: Renal Cell Carcinoma with Hepatic, Pulmonary and Brain Metastases
• Radiotherapy in Metastatic Urothelial Cancer and RCC
• RCC: Surgery in Metastatic Disease
• The Role of Surgery in Metastatic Bladder Cancer
• The Search for Biomarkers in RCC
• 10th European Multidisciplinary congress on Urological Cancers
• ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Singapore September 2018
• Bladder and Renal Cell Cancer
• Congress Highlights 1 - Genitourinary tumours, non-prostate
• A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Nivolumab Plus Ipilimumab in Patients (pts) With Localized Renal Cell Carcinoma (RCC)...
• PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with adv...
• Treatment-Free Interval (TFI) Following Discontinuation of First-Line Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Advan...
• Characterization of Response to Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Previously Untreated Advanced Renal Cell Ca...
• A new prognostic model for overall survival (OS) in second line (2L) for metastatic renal cell carcinoma (mRCC): Development and external validation
• First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase 1b JAVEL...
• TiNivo: Tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC).

• « Previous
• 1
• 2
• ...
• 21
• Next »